Viral Immunotherapy Development
Based on our experienced experts and advanced technology, Creative Biolabs is specialized in conducting data analysis for drug discovery, preclinical, and clinical studies. Our scientists provide global clients with powerful risk-based preclinical data verification services for developing drugs in viral immunotherapy.
Viral immunotherapy uses genetically engineered viruses to present a specific antigen to the immune system, including any virus/bacteria, or even human disease antigens, such as cancer antigens. Viruses are the most diverse and efficient gene-transfer agents, and they have an innate invasive ability to permit highly efficient antigen DNA delivery to cells and significantly enhance the immunogenicity of antigens carried within them. The features of viruses as vaccine vectors include their ability to induce immunological 'danger' signals at sites of infection and directly infect APCs.
Features of Virus Immunotherapy
Virus immunotherapy strategies commonly rely on replication-deficient viral vectors designed to deliver genes for tumor-associated antigens and growth factors. The most common viral vectors used in clinical trials are derived from such as retrovirus (RV), adenovirus (Ad), adeno-associated virus (AAV), and herpes simplex virus (HSV) and others. Each of the viruses has its unique advantages and limitations for immunotherapy applications and may require further modification for therapeutic use. An optimal viral immunotherapeutic vector should possess a number of properties. It should have the capability of inducing long-lasting immune responses for high immunogenicity, of delivering a large DNA cassette, inexpensive and easy to manufacture, and should be proven to be clinically safe and easy to administer.
Fig.1 Viral immunotherapy to enhance antigen targeting to antigen-presenting cells. (Pardoll, 2002)
Importance and Potential Risks
Vectors have represented tremendous promise in vaccination and/or strategies in various animal models against a vast number of cancers. Due to a number of features that make them attractive candidates for efficient vaccination strategies, viral vectors have been tested in clinical trials. However, there remain significant issues regarding the use of viral vectors for gene therapy strategies, including the high immunogenic for inducing active cellular and humoral immune responses and the risk of insertional mutagenesis. These limitations with viral vector-mediated gene therapy for diseases result in the possible safety and fatality issues in clinical trials. Due to the potential benefits of the viral-based system, safety modification to these vectors and efficacy improvement in terms of targeting modalities and use of adjuvants may result in the most potent immunotherapy systems in the fight against cancer.
Our Service for Viral Immunotherapy
Based on the outstanding expertise and rich experience, Creative Biolabs is dedicated to providing professional drug development consulting and data verification services for viral immunotherapy. Our powerful risk-based consulting platform focuses on project assessment, preclinical and clinical drug development. We serve our clients with the most reliable and qualified results to help you make an early decision about your project thus reducing investment risk.
With our excellent scientific team and advanced technology platform, Creative Biolabs offers our clients high-quality services that will significantly contribute to the success of their projects. Please do not hesitate to contact us.
Pardoll, D. M. Spinning molecular immunology into successful immunotherapy. Nature Reviews Immunology. 2002, 2(4): 227-238.